Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Phase 1, First-in-Human Study of CITY-RBP4 in Healthy Volunteers and STGD1 Participants

9. november 2026 opdateret af: City Therapeutics

A Phase 1, Randomized, Double-Masked, Placebo-Controlled, Single-Ascending and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CITY-RBP4 Administered Subcutaneously in Healthy Volunteers and Participants With Stargardt Disease Type 1 (STGD1)

This is a first-in-human (FIH), multicenter, randomized, double-masked, placebo-controlled adaptive clinical study evaluating the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) of CITY-RBP4, following single-ascending doses and multiple doses, via subcutaneous (SC) administration.

Studieoversigt

Status

Rekruttering

Detaljeret beskrivelse

The study consists of 3 sequential parts:

  • Part A: Single-ascending doses in healthy volunteers
  • Part B: Single-ascending doses in participants with Stargardt Disease Type 1 (STGD1)
  • Part C: Multiple doses in participants with Stargardt Disease Type 1 (STGD1)

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

48

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Victoria
      • Melbourne, Victoria, Australien, 3004

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

12 år til 45 år (Barn, Voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Key Inclusion Criteria (Part A):

  1. Willing and able to provide written informed consent form
  2. Be aged 18 to 45 years (inclusive) at the time of signing the informed consent form
  3. Generally healthy on medical history, exam, labs, and ECG
  4. BCVA 20/25 or better in each eye
  5. Serum retinol above protocol threshold
  6. Body weight ≥40 kg and BMI of 18.0 to 32.0 kg/m2
  7. Men and WOCBP must agree to use highly effective methods of contraception or practice abstinence from 30 days before the first dose of CITY-RBP4, throughout the study, and for at least 180 days after treatment with CITY-RBP4 or the last study visit, whichever is longer; men must refrain from donating or banking sperm during the same period
  8. Female participants who are not WOCBP should meet at least 1 of the following criteria: have undergone a documented hysterectomy, bilateral oophorectomy, and/or bilateral salpingectomy; have medically confirmed ovarian failure, or achieved postmenopausal status

Key Exclusion Criteria (Part A):

  1. Clinically significant ocular disease or prior ocular surgery that could interfere with safety assessments
  2. History of vitamin A deficiency, malabsorption, or chronic diarrhea
  3. Clinically significant cardiac, hepatic, renal, pulmonary, neurologic, or psychiatric disease
  4. Positive hepatitis B, hepatitis C, or HIV screening
  5. Prior RNAi/oligonucleotide therapy or recent investigational treatment
  6. Recent vitamin A-related supplements, retinoids, or medications affecting vitamin A metabolism
  7. Pregnancy or breastfeeding, if applicable

Key Inclusion Criteria (Parts B and C)

  1. Participants aged 12 to 45 years
  2. Clinical diagnosis of STGD1 with documented ABCA4 pathogenic/likely pathogenic variant
  3. Minimum BCVA is required in the study eye
  4. Subjects must have a defined aggregate atrophic lesion in 1 or both eyes
  5. Body weight ≥40 kg
  6. Able to complete key ophthalmic safety assessments and comply with study precautions

Key Exclusion Criteria (Parts B and C)

  1. Ocular conditions that could confound retinal imaging or safety evaluation
  2. Prior ocular gene therapy, stem cell therapy, or retinal implant
  3. Vitamin A deficiency or recent prohibited vitamin A-related treatments
  4. Recent interventional study participation
  5. Clinically significant non-ophthalmic disease, abnormal screening labs/ECG, or positive hepatitis B, hepatitis C, or HIV screening
  6. Pregnancy or breastfeeding, if applicable

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Sekventiel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: I Raske Voksne (Del A)

Saline (subcutaneous injection)

Eksperimentel: CITY-RBP4 in Healthy Adults (Part A)

siRNA (subcutaneous injection)

Eksperimentel: CITY-RBP4 in Participants with STGD1 (Parts B & C)

siRNA (subcutaneous injection)

Placebo komparator: In Participants with STGD1 (Parts B & C)

Saline (subcutaneous injection)

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence, severity, and relationship of treatment-emergent adverse events (TEAEs)
Tidsramme: Through study completion, up to Day 360

To evaluate the safety and tolerability of single and multiple doses of CITY-RBP4 in healthy adults and participants with Stargardt disease Type 1 (STGD1)

Through study completion, up to Day 360

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Plasma concentrations of CITY-RBP4
Tidsramme: Day 1 to Day 2

To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1

Day 1 to Day 2
Urine concentrations of CITY-RBP4
Tidsramme: Part A and B only: Day 1 to Day 2

To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after a single dose of CITY-RBP4 in healthy adults and participants with STGD1

Part A and B only: Day 1 to Day 2
Maximum plasma concentration (Cmax)
Tidsramme: Day 1 to Day 2

To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1

Day 1 to Day 2
Time to maximum plasma concentration (Tmax)
Tidsramme: Day 1 to Day 2

To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1

Day 1 to Day 2
Area under plasma concentration-time curve (AUC)
Tidsramme: Day 1 to Day 2

To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1

Day 1 to Day 2
Terminal elimination half-life (t1/2)
Tidsramme: Day 1 to Day 2

To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1

Day 1 to Day 2
Apparent clearance (CL/F)
Tidsramme: Day 1 to Day 2

To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1

Day 1 to Day 2
Amount excreted unchanged (Ae)
Tidsramme: Part A and B only: Day 1 to Day 2

To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after a single dose of CITY-RBP4 in healthy adults and participants with STGD1

Part A and B only: Day 1 to Day 2
Change from baseline in plasma RBP4 concentrations
Tidsramme: Up to Day 360

evaluate the pharmacodynamic (PD) effects of CITY-RBP4 on plasma retinol-binding protein 4 (RBP4) levels after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1

Up to Day 360
Change from baseline in serum retinol concentrations
Tidsramme: Up to Day 360

To evaluate the pharmacodynamic (PD) effects of CITY-RBP4 on serum retinol levels after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1

Up to Day 360

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studieleder: Medical Director, City Therapeutics

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

4. november 2026

Primær færdiggørelse (Anslået)

1. februar 2028

Studieafslutning (Anslået)

1. april 2028

Datoer for studieregistrering

Først indsendt

16. september 2026

Først indsendt, der opfyldte QC-kriterier

22. september 2026

Først opslået (Faktiske)

23. september 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

12. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

9. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner